Literature DB >> 12829002

Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency.

Toshihiro Shinka1, Masafumi Ohfu, Shinichi Hirose, Tomiko Kuhara.   

Abstract

The metabolic changes in a patient with succinic semialdehyde dehydrogenase deficiency were investigated following valproate administration using urease pretreatment and gas chromatography-mass spectrometry. A stable isotope dilution technique was used for quantification of urinary 4-hydroxybutyrate. Urinary levels of 4-hydroxybutyrate were 4-fold higher after 1-month valproate therapy. 4,5-Dihydrohexanoate, 2-deoxytetronate and 3-deoxytetronate were also 1.7-2.7-fold higher. The urinary excretions of 4-hydroxybutyrate in valproate non-medicated controls were age dependence and decreased with age. Relationships between 4-hydroxybutyrate excretion and 4-hydroxyvalproate or 5-hydroxyvalproate excretion were observed in valproate medicated controls. It seems that 4-hydroxyvalproate and 5-hydroxyvalproate as well as valproate are involved with increased excretion of 4-hydroxybutyrate following valproate administrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829002     DOI: 10.1016/s1570-0232(03)00276-9

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

2.  Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency.

Authors:  Elena Vanadia; K Michael Gibson; Phillip L Pearl; Emanuele Trapolino; Salvatore Mangano; Francesca Vanadia
Journal:  JIMD Rep       Date:  2012-08-22

3.  Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Phillip L Pearl; Lovy Shukla; William H Theodore; Cornelis Jakobs; K Michael Gibson
Journal:  Brain Dev       Date:  2011-06-12       Impact factor: 1.961

Review 4.  The pharmacogenomics of valproic acid.

Authors:  Miao-Miao Zhu; Hui-Lan Li; Li-Hong Shi; Xiao-Ping Chen; Jia Luo; Zan-Ling Zhang
Journal:  J Hum Genet       Date:  2017-09-07       Impact factor: 3.172

Review 5.  Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification.

Authors:  Phillip L Pearl; Mahsa Parviz; Kara Vogel; John Schreiber; William H Theodore; K Michael Gibson
Journal:  Dev Med Child Neurol       Date:  2014-12-29       Impact factor: 5.449

Review 6.  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.

Authors:  P L Pearl; K M Gibson; M A Cortez; Y Wu; O Carter Snead; I Knerr; K Forester; J M Pettiford; C Jakobs; W H Theodore
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

Review 7.  Seizures and metabolic disease.

Authors:  Phillip L Pearl; Heather D Bennett; Zarir Khademian
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

8.  Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies.

Authors:  Mahsa Parviz; Kara Vogel; K Michael Gibson; Phillip L Pearl
Journal:  J Pediatr Epilepsy       Date:  2014-11-25

9.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

10.  Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.

Authors:  Ina Knerr; K Michael Gibson; Cornelis Jakobs; Phillip L Pearl
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.